Resources

The COVID-19 pandemic defined 2020 for PATH and for the world. As COVID-19 case numbers grew over the first half of the year and access to routine health services decreased, we knew we needed to act quickly to help protect health equity for all. The health of our communities—as well as the hard-won gains of the past several years of health advocacy—were at risk. With support from the Bill & Melinda Gates Foundation, PATH pivoted many of our planned efforts to focus on protecting essential health services and helping governments respond to the pandemic—all while keeping our goals for the future top of mind. This case study highlights some of the new tactics we took on, and lessons learned, in this unprecedented year.

This policy brief highlights the importance of family planning supply chain in ensuring diverse and inclusive family planning and reproductive health outcomes in India, in alignment with sustainable development goals.

In February 2019, PATH and the US President’s Malaria Initiative, in partnership with Zambia’s National Malaria Elimination Programme (NMEP), conducted a stakeholder assessment to explore the ways in which stakeholders’ perceptions of malaria elimination had changed (or had not changed) since 2015, when a baseline stakeholder assessment had been conducted. Stakeholders were asked about Zambia’s malaria targets and objectives, as described in the National Malaria Elimination Strategic Plan 2017–2021. Interviews also aimed to capture views around what was needed to accelerate progress towards national targets, as well as opportunities and barriers—technical, financial, and operational—for increasing the prominence of malaria on the national health agenda. The analysis of stakeholder responses is intended to inform future programme evaluation and strategy development to accelerate progress towards the reduction and elimination of the malaria burden in Zambia.

In February 2019, PATH and the US President’s Malaria Initiative, in partnership with Zambia’s National Malaria Elimination Programme (NMEP), conducted a stakeholder assessment to explore the ways in which stakeholders’ perceptions of malaria elimination had changed (or had not changed) since 2015, when a baseline stakeholder assessment had been conducted. This report brief summarizes the findings of the assessment.

The Safeprim study evaluated the operational aspects of the SD Biosensor STANDARD™ G6PD screening test performed in real-life settings of two municipalities in the Brazilian Amazon. In order to provide suitable training for health care professionals with different backgrounds at the primary level of care, job aids were created based on materials available within the G6PD Operational Research Community of Practice hosted by PATH. This way, the essential information on test procedure, treatment choice, and pharmacovigilance of hemolysis could be used in the field after a 4-hour training session.A wall poster (29.7x42 cm), folder (21x29.7 cm), and slide set were used during the trainings, while patient cards (8x20 cm malaria card) containing G6PD and malaria data were provided after screening: a green-colored card for normal G6PD status and red-colored card for G6PD deficient. Such cards could be referenced in future malaria episodes.